Jespersen C M
Københavns Kommune Hospital, Copenhagen, Denmark.
J Cardiovasc Pharmacol. 1991;18 Suppl 6:S30-2.
The effect of verapamil on death and reinfarction in patients with and without exercise-induced myocardial ischemia after acute myocardial infarction was studied in a double-blind, placebo-controlled multicenter study. Two hundred ninety-eight patients were included. A symptom-limited exercise test was carried out 9 days after the myocardial infarction but before randomization. Forty-four patients with and 111 without exercise-induced ischemia were randomly assigned to verapamil and 39 and 104, respectively, to placebo treatment. The patients were observed for 18 months. The overall 18-month event rate was 12.1%. The lowest event rate was seen in patients with myocardial ischemia and verapamil treatment (9.1%), and the highest in patients with myocardial ischemia receiving a placebo (15.4%), while rates of patients without ischemia were sandwiched in between (12.5 and 12.6%). The differences were not statistically significant.
在一项双盲、安慰剂对照的多中心研究中，研究了维拉帕米对急性心肌梗死后伴有或不伴有运动诱发心肌缺血患者的死亡和再梗死的影响。共纳入298例患者。在心肌梗死后9天但在随机分组前进行了症状限制性运动试验。44例有运动诱发缺血的患者和111例无运动诱发缺血的患者被随机分配接受维拉帕米治疗，分别有39例和104例被分配接受安慰剂治疗。对患者进行了18个月的观察。18个月的总体事件发生率为12.1%。心肌缺血且接受维拉帕米治疗的患者事件发生率最低（9.1%），接受安慰剂治疗的心肌缺血患者事件发生率最高（15.4%），而无缺血患者的发生率介于两者之间（12.5%和12.6%）。差异无统计学意义。
